Whats new

Whats new.

Maxim Group - New P2/3 AIPAC-003 Study Initiated with More Aggressive Dosing and OS Primary in Breast Cancer; Rating Buy, $8 tgt (Analyst: Jason McCarthy, PhD)

March 14th 2023

For a copy of this analyst report please contact your Maxim analyst Jason McCarthy - jmccarthy@maximgrp.com

Go back